House Republicans Push Cannabis Rescheduling Block Despite Trump Backing
GOP appropriators advance funding bill to halt federal marijuana rescheduling as administration signals support for reform, creating regulatory uncertainty.
House Republicans are advancing appropriations language designed to prevent federal marijuana rescheduling, creating a direct conflict with the Trump administration's stated support for cannabis reform. The House Appropriations Subcommittee on Commerce, Justice, Science, and Related Agencies released funding bill text Wednesday containing provisions that would block the Drug Enforcement Administration from implementing any rescheduling decision.
The congressional pushback introduces fresh uncertainty into cannabis markets already navigating complex federal-state regulatory dynamics. Multi-state operators like Curaleaf (CURA), Green Thumb Industries (GTII), and Trulieve (TCNNF) have built business models anticipating eventual federal reform, particularly the elimination of 280E tax restrictions that currently limit deductible business expenses for cannabis companies.
The political divide within Republican ranks highlights the evolving cannabis policy landscape. While Trump administration officials signal openness to rescheduling marijuana from Schedule I to Schedule III, congressional Republicans maintain traditional opposition. This disconnect creates operational challenges for cannabis companies planning capital allocation and expansion strategies around potential federal changes.
For publicly traded cannabis operators, the regulatory uncertainty compounds existing market pressures. Most major MSOs trade on Canadian exchanges due to federal prohibition, limiting institutional investment and creating liquidity constraints. Any delay or reversal of rescheduling progress could extend these market access limitations and maintain current tax disadvantages that significantly impact profit margins.
The appropriations process provides Republicans a procedural mechanism to influence cannabis policy even without broader legislative support for prohibition. However, the funding bill faces Senate consideration where Democratic support for cannabis reform remains stronger. Cannabis companies and investors now monitor both executive branch rescheduling timelines and congressional funding negotiations that could determine the pace and scope of federal cannabis policy changes through 2024.